nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—SLC6A3—attention deficit hyperactivity disorder	0.342	0.431	CbGaD
Paroxetine—SLC6A4—attention deficit hyperactivity disorder	0.255	0.322	CbGaD
Paroxetine—HTR2A—attention deficit hyperactivity disorder	0.196	0.247	CbGaD
Paroxetine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00875	0.131	CbGeAlD
Paroxetine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00526	0.0785	CbGeAlD
Paroxetine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00465	0.0694	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00279	0.0417	CbGeAlD
Paroxetine—TACR1—forebrain—attention deficit hyperactivity disorder	0.00267	0.0399	CbGeAlD
Paroxetine—TACR1—nervous system—attention deficit hyperactivity disorder	0.00145	0.0216	CbGeAlD
Paroxetine—TACR1—central nervous system—attention deficit hyperactivity disorder	0.0014	0.0208	CbGeAlD
Paroxetine—CHRM4—nervous system—attention deficit hyperactivity disorder	0.00136	0.0204	CbGeAlD
Paroxetine—CHRM2—forebrain—attention deficit hyperactivity disorder	0.00135	0.0201	CbGeAlD
Paroxetine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00134	0.0201	CbGeAlD
Paroxetine—CHRM4—central nervous system—attention deficit hyperactivity disorder	0.00131	0.0196	CbGeAlD
Paroxetine—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00123	0.0184	CbGeAlD
Paroxetine—CHRM1—forebrain—attention deficit hyperactivity disorder	0.00123	0.0183	CbGeAlD
Paroxetine—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00114	0.017	CbGeAlD
Paroxetine—TACR1—brain—attention deficit hyperactivity disorder	0.00111	0.0165	CbGeAlD
Paroxetine—CHRM3—forebrain—attention deficit hyperactivity disorder	0.0011	0.0164	CbGeAlD
Paroxetine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00108	0.0162	CbGeAlD
Paroxetine—CHRM5—nervous system—attention deficit hyperactivity disorder	0.00107	0.0159	CbGeAlD
Paroxetine—CHRM4—brain—attention deficit hyperactivity disorder	0.00104	0.0156	CbGeAlD
Paroxetine—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.00104	0.0155	CbGeAlD
Paroxetine—CHRM5—central nervous system—attention deficit hyperactivity disorder	0.00103	0.0153	CbGeAlD
Paroxetine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.000887	0.0132	CbGeAlD
Paroxetine—CHRM5—brain—attention deficit hyperactivity disorder	0.000814	0.0122	CbGeAlD
Paroxetine—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000813	0.0121	CbGeAlD
Paroxetine—CHRM2—nervous system—attention deficit hyperactivity disorder	0.000731	0.0109	CbGeAlD
Paroxetine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000729	0.0109	CbGeAlD
Paroxetine—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.000704	0.0105	CbGeAlD
Paroxetine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000702	0.0105	CbGeAlD
Paroxetine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000686	0.0102	CbGeAlD
Paroxetine—CYP2B6—cardiovascular system—attention deficit hyperactivity disorder	0.000675	0.0101	CbGeAlD
Paroxetine—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.000669	0.00998	CbGeAlD
Paroxetine—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000668	0.00998	CbGeAlD
Paroxetine—CHRM1—nervous system—attention deficit hyperactivity disorder	0.000666	0.00994	CbGeAlD
Paroxetine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000651	0.00973	CbGeAlD
Paroxetine—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000643	0.00961	CbGeAlD
Paroxetine—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000641	0.00957	CbGeAlD
Paroxetine—CHRM3—nervous system—attention deficit hyperactivity disorder	0.000596	0.0089	CbGeAlD
Paroxetine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000593	0.00886	CbGeAlD
Paroxetine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000588	0.00878	CbGeAlD
Paroxetine—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.000573	0.00856	CbGeAlD
Paroxetine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000566	0.00846	CbGeAlD
Paroxetine—CHRM2—brain—attention deficit hyperactivity disorder	0.000559	0.00835	CbGeAlD
Paroxetine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000557	0.00832	CbGeAlD
Paroxetine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000551	0.00822	CbGeAlD
Paroxetine—SLC6A4—brain—attention deficit hyperactivity disorder	0.000511	0.00763	CbGeAlD
Paroxetine—CHRM1—brain—attention deficit hyperactivity disorder	0.000509	0.0076	CbGeAlD
Paroxetine—CHRM3—brain—attention deficit hyperactivity disorder	0.000455	0.0068	CbGeAlD
Paroxetine—SLC6A2—brain—attention deficit hyperactivity disorder	0.00045	0.00671	CbGeAlD
Paroxetine—CYP2B6—nervous system—attention deficit hyperactivity disorder	0.000433	0.00647	CbGeAlD
Paroxetine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.00043	0.00642	CbGeAlD
Paroxetine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000427	0.00637	CbGeAlD
Paroxetine—CYP2B6—central nervous system—attention deficit hyperactivity disorder	0.000417	0.00623	CbGeAlD
Paroxetine—CYP2C8—brain—attention deficit hyperactivity disorder	0.000369	0.00552	CbGeAlD
Paroxetine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000361	0.00539	CbGeAlD
Paroxetine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000354	0.00528	CbGeAlD
Paroxetine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.00034	0.00508	CbGeAlD
Paroxetine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000333	0.00497	CbGeAlD
Paroxetine—CYP2B6—brain—attention deficit hyperactivity disorder	0.000331	0.00495	CbGeAlD
Paroxetine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000322	0.00481	CbGeAlD
Paroxetine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00031	0.00463	CbGeAlD
Paroxetine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000303	0.00453	CbGeAlD
Paroxetine—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000282	0.00421	CbGeAlD
Paroxetine—HTR2A—brain—attention deficit hyperactivity disorder	0.00027	0.00404	CbGeAlD
Paroxetine—CYP2D6—brain—attention deficit hyperactivity disorder	0.000246	0.00368	CbGeAlD
Paroxetine—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000232	0.00346	CbGeAlD
Paroxetine—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000223	0.00333	CbGeAlD
Paroxetine—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000218	0.00326	CbGeAlD
Paroxetine—ABCB1—brain—attention deficit hyperactivity disorder	0.000177	0.00264	CbGeAlD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	4.99e-05	0.000356	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.91e-05	0.000351	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.88e-05	0.000349	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.87e-05	0.000348	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.86e-05	0.000347	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.82e-05	0.000344	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.81e-05	0.000344	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.78e-05	0.000341	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.67e-05	0.000334	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.59e-05	0.000328	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.57e-05	0.000326	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.56e-05	0.000326	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.55e-05	0.000325	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.54e-05	0.000324	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.52e-05	0.000323	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.51e-05	0.000322	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.49e-05	0.000321	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.48e-05	0.00032	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.47e-05	0.000319	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.45e-05	0.000318	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.45e-05	0.000318	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.43e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.39e-05	0.000314	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.37e-05	0.000312	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.36e-05	0.000312	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.35e-05	0.000311	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.33e-05	0.000309	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.26e-05	0.000304	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.26e-05	0.000304	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.24e-05	0.000303	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.21e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.18e-05	0.000298	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	4.17e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.11e-05	0.000293	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	4.1e-05	0.000293	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.09e-05	0.000292	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.06e-05	0.00029	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.04e-05	0.000288	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.99e-05	0.000285	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.93e-05	0.000281	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.92e-05	0.00028	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.9e-05	0.000278	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.88e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.87e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.86e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.83e-05	0.000273	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.82e-05	0.000273	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.72e-05	0.000265	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.65e-05	0.000261	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.58e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.56e-05	0.000255	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.56e-05	0.000254	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.55e-05	0.000254	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.54e-05	0.000253	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.52e-05	0.000251	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.52e-05	0.000251	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.51e-05	0.000251	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.47e-05	0.000248	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.42e-05	0.000244	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.41e-05	0.000243	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.41e-05	0.000243	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	3.39e-05	0.000242	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.39e-05	0.000242	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.38e-05	0.000241	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.37e-05	0.000241	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.35e-05	0.000239	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.34e-05	0.000239	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.17e-05	0.000226	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.15e-05	0.000225	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.14e-05	0.000224	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.14e-05	0.000224	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.11e-05	0.000222	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.09e-05	0.000221	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.08e-05	0.00022	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.08e-05	0.00022	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.08e-05	0.00022	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.07e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.07e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.06e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.05e-05	0.000218	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.05e-05	0.000218	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.04e-05	0.000217	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.04e-05	0.000217	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.02e-05	0.000216	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.02e-05	0.000215	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.01e-05	0.000215	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.01e-05	0.000215	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.99e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.99e-05	0.000213	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.98e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.96e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.96e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.96e-05	0.000211	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.96e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.95e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.95e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.94e-05	0.00021	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.93e-05	0.000209	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.92e-05	0.000209	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.9e-05	0.000207	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.88e-05	0.000205	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.87e-05	0.000205	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.86e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.85e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.82e-05	0.000202	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.78e-05	0.000199	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.77e-05	0.000198	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.77e-05	0.000198	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.76e-05	0.000197	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.76e-05	0.000197	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.75e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.74e-05	0.000196	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.74e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.73e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.72e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.72e-05	0.000194	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.71e-05	0.000194	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.7e-05	0.000193	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.7e-05	0.000193	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.69e-05	0.000192	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.69e-05	0.000192	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.68e-05	0.000191	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.66e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.65e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.6e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.58e-05	0.000184	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	2.52e-05	0.00018	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.52e-05	0.00018	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.52e-05	0.00018	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.51e-05	0.000179	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.51e-05	0.000179	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.5e-05	0.000178	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.49e-05	0.000178	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	2.48e-05	0.000177	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.47e-05	0.000177	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	2.43e-05	0.000174	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.43e-05	0.000173	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.4e-05	0.000171	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.39e-05	0.00017	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.36e-05	0.000168	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.32e-05	0.000166	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.32e-05	0.000165	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.3e-05	0.000165	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.28e-05	0.000163	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.26e-05	0.000161	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	2.23e-05	0.00016	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.19e-05	0.000157	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.18e-05	0.000156	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.17e-05	0.000155	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.17e-05	0.000155	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.16e-05	0.000155	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.13e-05	0.000152	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.1e-05	0.00015	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.09e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.08e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.07e-05	0.000148	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.05e-05	0.000147	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.01e-05	0.000144	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.98e-05	0.000142	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.93e-05	0.000138	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.93e-05	0.000138	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.92e-05	0.000137	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.91e-05	0.000136	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	1.84e-05	0.000131	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.84e-05	0.000131	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.83e-05	0.000131	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.82e-05	0.00013	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.81e-05	0.000129	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	1.81e-05	0.000129	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.79e-05	0.000128	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.77e-05	0.000127	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.75e-05	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.75e-05	0.000125	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.73e-05	0.000124	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.73e-05	0.000124	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.7e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.69e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.68e-05	0.00012	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.68e-05	0.00012	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.67e-05	0.000119	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.65e-05	0.000118	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.65e-05	0.000118	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.64e-05	0.000117	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.63e-05	0.000117	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.62e-05	0.000116	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.62e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.61e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.6e-05	0.000115	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.6e-05	0.000114	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.6e-05	0.000114	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.6e-05	0.000114	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.59e-05	0.000113	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.59e-05	0.000113	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.58e-05	0.000113	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.57e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.57e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.54e-05	0.00011	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	1.53e-05	0.000109	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	1.52e-05	0.000108	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.51e-05	0.000108	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.51e-05	0.000108	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	1.49e-05	0.000107	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.49e-05	0.000107	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.49e-05	0.000106	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.48e-05	0.000106	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.48e-05	0.000106	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.48e-05	0.000105	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.47e-05	0.000105	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	1.47e-05	0.000105	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.47e-05	0.000105	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.46e-05	0.000104	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.46e-05	0.000104	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.4e-05	9.97e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.38e-05	9.84e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.37e-05	9.76e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	1.31e-05	9.38e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.3e-05	9.31e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.28e-05	9.13e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.22e-05	8.69e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.2e-05	8.6e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.19e-05	8.53e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.15e-05	8.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.14e-05	8.12e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	1.11e-05	7.94e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	1.1e-05	7.88e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.07e-05	7.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.04e-05	7.4e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.03e-05	7.38e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.02e-05	7.31e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	9.69e-06	6.92e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	9.62e-06	6.87e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	9.13e-06	6.52e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	9.06e-06	6.47e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	9.05e-06	6.46e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	8.98e-06	6.42e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.71e-06	6.22e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.14e-06	5.82e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.8e-06	5.57e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	6.55e-06	4.68e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	5.63e-06	4.02e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.52e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.49e-06	3.92e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.47e-06	3.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.42e-06	3.87e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	4.77e-06	3.41e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	4.15e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	3.91e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	3.88e-06	2.77e-05	CbGpPWpGaD
